JP2015509716A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509716A5 JP2015509716A5 JP2014558875A JP2014558875A JP2015509716A5 JP 2015509716 A5 JP2015509716 A5 JP 2015509716A5 JP 2014558875 A JP2014558875 A JP 2014558875A JP 2014558875 A JP2014558875 A JP 2014558875A JP 2015509716 A5 JP2015509716 A5 JP 2015509716A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- cell
- car
- cells
- antigen binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000011664 signaling Effects 0.000 claims description 80
- 239000000427 antigen Substances 0.000 claims description 64
- 108091007433 antigens Proteins 0.000 claims description 64
- 102000036639 antigens Human genes 0.000 claims description 64
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 63
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 59
- 230000000139 costimulatory effect Effects 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 36
- 210000004027 cell Anatomy 0.000 claims description 34
- 150000007523 nucleic acids Chemical group 0.000 claims description 26
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 24
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 16
- 241000124008 Mammalia Species 0.000 claims description 11
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 8
- 102100027207 CD27 antigen Human genes 0.000 claims description 8
- 101150013553 CD40 gene Proteins 0.000 claims description 8
- 102100035793 CD83 antigen Human genes 0.000 claims description 8
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 8
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 8
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims description 8
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 8
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 8
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 8
- -1 ICOS Proteins 0.000 claims description 8
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims description 8
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 8
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 8
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 8
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 8
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 8
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 8
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 230000003834 intracellular effect Effects 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 8
- 230000004913 activation Effects 0.000 claims description 5
- 230000005809 anti-tumor immunity Effects 0.000 claims description 5
- 230000009460 calcium influx Effects 0.000 claims description 5
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 4
- 210000003289 regulatory T cell Anatomy 0.000 claims description 4
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 2
- 229930186217 Glycolipid Natural products 0.000 claims description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 2
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 2
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 2
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 2
- 102000003735 Mesothelin Human genes 0.000 claims description 2
- 108090000015 Mesothelin Proteins 0.000 claims description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 2
- 230000006786 activation induced cell death Effects 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 claims description 2
- 238000012737 microarray-based gene expression Methods 0.000 claims description 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 26
- 241000282412 Homo Species 0.000 claims 2
- 230000002068 genetic effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261601907P | 2012-02-22 | 2012-02-22 | |
| US61/601,907 | 2012-02-22 | ||
| PCT/US2013/027361 WO2013126729A1 (en) | 2012-02-22 | 2013-02-22 | Use of the cd2 signaling domain in second-generation chimeric antigen receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015509716A JP2015509716A (ja) | 2015-04-02 |
| JP2015509716A5 true JP2015509716A5 (enExample) | 2016-04-07 |
Family
ID=49006248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014558875A Withdrawn JP2015509716A (ja) | 2012-02-22 | 2013-02-22 | 第二世代キメラ抗原受容体におけるｃｄ２シグナル伝達ドメインの使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US9783591B2 (enExample) |
| EP (2) | EP2817331B1 (enExample) |
| JP (1) | JP2015509716A (enExample) |
| KR (1) | KR20140127829A (enExample) |
| CN (1) | CN104136458A (enExample) |
| AU (1) | AU2013222284A1 (enExample) |
| BR (1) | BR112014020502A2 (enExample) |
| CA (1) | CA2864489C (enExample) |
| EA (1) | EA201491573A1 (enExample) |
| ES (1) | ES2959443T3 (enExample) |
| IL (1) | IL233993A0 (enExample) |
| IN (1) | IN2014DN06522A (enExample) |
| MX (1) | MX2014010185A (enExample) |
| SG (1) | SG11201404284SA (enExample) |
| WO (1) | WO2013126729A1 (enExample) |
Families Citing this family (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014020502A2 (pt) * | 2012-02-22 | 2019-09-24 | Univ Pennsylvania | sequência de ácido nucleico isolada, receptor quimérico de antígeno isolado, célula, vetor, e, métodos para estimular uma resposta imune, para fornecer uma imunidade antitumoral, para tratamento de um mamífero, para gerar e para expandir uma população de células - t, e para modular a quantidade de citocina secretada por uma célula -t |
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| SG11201505896YA (en) | 2013-02-20 | 2015-09-29 | Novartis Ag | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| WO2014130635A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
| ES2769574T3 (es) | 2013-03-15 | 2020-06-26 | Michael C Milone | Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| ES2918501T3 (es) | 2013-12-19 | 2022-07-18 | Novartis Ag | Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos |
| WO2015090229A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
| EP3097117B1 (en) | 2014-01-21 | 2023-10-04 | Novartis Ag | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| SG10202109752XA (en) | 2014-04-07 | 2021-10-28 | Novartis Ag | Treatment of cancer using anti-cd19 chimeric antigen receptor |
| US11041021B2 (en) | 2014-05-23 | 2021-06-22 | University Of Florida Research Foundation, Incorporated | Car based immunotherapy |
| JP6831777B2 (ja) | 2014-07-21 | 2021-02-17 | ノバルティス アーゲー | Ｃｄ３３キメラ抗原受容体を使用する癌の処置 |
| WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| BR112017000939A2 (pt) | 2014-07-21 | 2017-11-14 | Novartis Ag | tratamento de câncer usando um receptor antigênico quimérico de cll-1 |
| AU2015292744C1 (en) | 2014-07-21 | 2021-01-21 | Novartis Ag | Treatment of cancer using humanized anti-BCMA chimeric antigen receptor |
| EP3712171A1 (en) | 2014-08-19 | 2020-09-23 | Novartis AG | Treatment of cancer using a cd123 chimeric antigen receptor |
| DK3186284T3 (da) | 2014-08-28 | 2022-05-09 | Bioatla Inc | Betinget aktive kimæriske antigenreceptorer til modificerede t-celler |
| US10577417B2 (en) | 2014-09-17 | 2020-03-03 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| AU2015330898B2 (en) | 2014-10-08 | 2022-03-10 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
| RS63601B1 (sr) * | 2014-10-09 | 2022-10-31 | Univ Yamaguchi | Vektor ekspresije car i t ćelije koje eksprimiraju car |
| RU2751362C2 (ru) | 2014-12-29 | 2021-07-13 | Новартис Аг | Способы получения экспрессирующих химерный антигенный рецептор клеток |
| US11459390B2 (en) | 2015-01-16 | 2022-10-04 | Novartis Ag | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor |
| EP3250602A1 (en) | 2015-01-26 | 2017-12-06 | Cellectis | T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm |
| CN113862292B (zh) * | 2015-01-29 | 2024-12-27 | 明尼苏达大学董事会 | 嵌合抗原受体、组合物以及方法 |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| US10647778B2 (en) | 2015-02-09 | 2020-05-12 | University Of Florida Research Foundation, Incorporated | Bi-specific chimeric antigen receptor and uses thereof |
| US11248058B2 (en) | 2015-02-19 | 2022-02-15 | University Of Florida Research Foundation, Inc. | Chimeric antigen receptors and uses thereof |
| PL3280729T3 (pl) | 2015-04-08 | 2022-08-22 | Novartis Ag | Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19 |
| WO2016168595A1 (en) | 2015-04-17 | 2016-10-20 | Barrett David Maxwell | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| CN105198790B (zh) * | 2015-04-20 | 2018-02-16 | 范国煌 | 促进双阴性t细胞体外增殖的四环化合物 |
| WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| EP3770168A1 (en) * | 2015-05-18 | 2021-01-27 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| US11370845B2 (en) | 2015-06-24 | 2022-06-28 | Keio University | Anti-glypican-1-immunizing antigen receptor |
| WO2017011316A1 (en) * | 2015-07-10 | 2017-01-19 | The Trustees Of The University Of Pennsylvania | Treatment of a canine cd20 positive disease or condition using a canine cd20-specific chimeric antigen receptor |
| US10829735B2 (en) | 2015-07-21 | 2020-11-10 | The Trustees Of The University Of Pennsylvania | Methods for improving the efficacy and expansion of immune cells |
| GB201513540D0 (en) | 2015-07-31 | 2015-09-16 | King S College London | Therapeutic agents |
| US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| WO2017040324A1 (en) * | 2015-08-28 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
| WO2017040195A1 (en) * | 2015-08-28 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
| WO2017040930A2 (en) | 2015-09-03 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Biomarkers predictive of cytokine release syndrome |
| MX2018005618A (es) * | 2015-11-05 | 2018-08-01 | Juno Therapeutics Inc | Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados. |
| WO2017093969A1 (en) | 2015-12-04 | 2017-06-08 | Novartis Ag | Compositions and methods for immunooncology |
| PT3393504T (pt) | 2015-12-22 | 2025-12-30 | Novartis Ag | Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena |
| CN110699371A (zh) * | 2016-03-18 | 2020-01-17 | 江苏普瑞康生物医药科技有限公司 | 一种基于FcγRⅢa的嵌合基因及其用途 |
| EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
| CN113082201B (zh) * | 2016-04-01 | 2024-07-05 | 上海斯丹赛生物技术有限公司 | 刺激t细胞介导的对表达抗原的细胞群的免疫应答的方法 |
| CA3019835A1 (en) | 2016-04-08 | 2017-10-12 | Purdue Research Foundation | Methods and compositions for car t cell therapy |
| WO2017190096A1 (en) | 2016-04-29 | 2017-11-02 | University Of Florida Research Foundation Incorporated | Chimeric antigen receptors and uses thereof |
| EP4122958A1 (en) | 2016-05-13 | 2023-01-25 | BioAtla, Inc. | Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| WO2018026953A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| US12350349B2 (en) | 2016-08-03 | 2025-07-08 | Washington University | Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors |
| PL3896091T3 (pl) | 2016-08-10 | 2024-04-29 | Legend Biotech Ireland Limited | Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania |
| WO2018058432A1 (zh) * | 2016-09-28 | 2018-04-05 | 李华顺 | 一种多基因重组嵌合抗原受体分子及其应用 |
| JP7467117B2 (ja) | 2016-10-07 | 2024-04-15 | ノバルティス アーゲー | 癌の治療のためのキメラ抗原受容体 |
| BR112019007100A2 (pt) | 2016-10-07 | 2019-06-25 | Tcr2 Therapeutics Inc | composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão |
| CN110177803A (zh) | 2016-11-22 | 2019-08-27 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重新编程的组合物和方法 |
| CN106754725A (zh) * | 2016-12-26 | 2017-05-31 | 北京普瑞金科技有限公司 | 一种嵌合抗原受体t细胞及其制备方法与应用 |
| US11535662B2 (en) | 2017-01-26 | 2022-12-27 | Novartis Ag | CD28 compositions and methods for chimeric antigen receptor therapy |
| AU2018219226B2 (en) | 2017-02-07 | 2024-12-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| CN110582288B (zh) | 2017-02-28 | 2024-09-20 | 恩多塞特公司 | 用于car t细胞疗法的组合物和方法 |
| KR20190130608A (ko) | 2017-03-22 | 2019-11-22 | 노파르티스 아게 | 면역종양학을 위한 조성물 및 방법 |
| JP2020517259A (ja) | 2017-04-19 | 2020-06-18 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 操作された抗原受容体を発現する免疫細胞 |
| AU2018292181B2 (en) | 2017-06-30 | 2025-04-10 | Cellectis | Cellular immunotherapy for repetitive administration |
| CA3076337A1 (en) | 2017-09-19 | 2019-03-28 | Massachusetts Institute Of Technology | Compositions for chimeric antigen receptor t cell therapy and uses thereof |
| SG11202003415XA (en) | 2017-10-18 | 2020-05-28 | Novartis Ag | Compositions and methods for selective protein degradation |
| US20200283501A1 (en) | 2017-10-26 | 2020-09-10 | Regents Of The University Of Minnesota | Recombinant immune cells, methods of making, and methods of use |
| CN107880128B (zh) * | 2017-12-21 | 2021-03-02 | 常州费洛斯药业科技有限公司 | 一种抗cd19的全人源抗体或抗体片段及其方法和应用 |
| CN111867619A (zh) | 2018-01-03 | 2020-10-30 | 曲生物制品公司 | 过继性细胞治疗的先天寻靶 |
| WO2019136432A1 (en) | 2018-01-08 | 2019-07-11 | Novartis Ag | Immune-enhancing rnas for combination with chimeric antigen receptor therapy |
| WO2019144095A1 (en) | 2018-01-22 | 2019-07-25 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for car t cells |
| AU2019218729B2 (en) | 2018-02-06 | 2025-12-04 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors |
| CN110129369B (zh) * | 2018-02-09 | 2023-10-13 | 上海交通大学医学院附属上海儿童医学中心 | 一种嵌合抗原受体基因工程载体、免疫细胞及其应用 |
| WO2019165121A1 (en) | 2018-02-21 | 2019-08-29 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses therof |
| JP7568224B2 (ja) | 2018-02-23 | 2024-10-16 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための配列決定法 |
| CN108715859B (zh) * | 2018-05-31 | 2021-08-03 | 中国医学科学院血液病医院(中国医学科学院血液学研究所) | 靶向cd22的嵌合抗原受体及其应用 |
| IL279367B2 (en) | 2018-06-13 | 2026-05-01 | Novartis Ag | BCMA chimeric antigen receptors and their uses |
| EP3826625A4 (en) | 2018-07-23 | 2022-08-24 | Magenta Therapeutics, Inc. | USE OF ANTI-CD5 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENE CELL THERAPY |
| SI3844267T1 (sl) | 2018-08-31 | 2025-10-30 | Novartis Ag | Postopki izdelave celic, ki izražajo receptorje himernega antigena |
| SG11202100935TA (en) | 2018-09-28 | 2021-02-25 | Massachusetts Inst Technology | Collagen-localized immunomodulatory molecules and methods thereof |
| US12168781B2 (en) | 2018-12-06 | 2024-12-17 | Kirin Holdings Kabushiki Kaisha | Production method for T cells or NK cells, medium for culturing T cells or NK cells, method for culturing T cells or NK cells, method for maintaining undifferentiated state of undifferentiated T cells, and growth-accelerating agent for T cells or NK cells |
| US20220062341A1 (en) | 2018-12-26 | 2022-03-03 | Kirin Holdings Kabushiki Kaisha | Modified tcr and production method therefor |
| US12600971B2 (en) | 2019-02-13 | 2026-04-14 | Beam Therapeutics Inc. | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| TW202042824A (zh) | 2019-03-27 | 2020-12-01 | 賓夕法尼亞大學董事會 | Tn-MUC1嵌合抗原受體（CAR）T細胞療法 |
| JP2022538974A (ja) | 2019-06-26 | 2022-09-07 | マサチューセッツ インスチテュート オブ テクノロジー | 免疫調節融合タンパク質－金属水酸化物錯体およびその方法 |
| WO2021061648A1 (en) | 2019-09-23 | 2021-04-01 | Massachusetts Institute Of Technology | Methods and compositions for stimulation of endogenous t cell responses |
| US12594301B2 (en) | 2019-09-27 | 2026-04-07 | Beam Therapeutics Inc. | Compositions and methods for treatment of liquid cancers |
| WO2021108661A2 (en) | 2019-11-26 | 2021-06-03 | Novartis Ag | Chimeric antigen receptors and uses thereof |
| JP7805928B2 (ja) | 2019-11-26 | 2026-01-26 | ノバルティス アーゲー | Ｃｄ１９及びｃｄ２２キメラ抗原受容体及びその使用 |
| IL295063A (en) | 2020-02-04 | 2022-09-01 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Chimeric antigen receptors (car) against dinitrophenol |
| CN115698285A (zh) * | 2020-02-14 | 2023-02-03 | 小利兰·斯坦福大学董事会 | 具有cd2激活的嵌合抗原受体 |
| JP2023517011A (ja) | 2020-03-05 | 2023-04-21 | ネオティーエックス セラピューティクス リミテッド | 免疫細胞を用いて癌を治療するための方法および組成物 |
| IL296242A (en) | 2020-03-10 | 2022-11-01 | Massachusetts Inst Technology | Methods for generating engineered memory-like nk cells and compositions thereof |
| US11896619B2 (en) | 2020-03-10 | 2024-02-13 | Massachusetts Institute Of Technology | Compositions and methods for immunotherapy of NPM1c-positive cancer |
| US20210340524A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
| US12433954B2 (en) | 2020-05-01 | 2025-10-07 | Massachusetts Institute Of Technology | Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs |
| AU2021347359A1 (en) * | 2020-09-25 | 2023-05-18 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| WO2022086620A1 (en) * | 2020-10-20 | 2022-04-28 | The Methodist Hospital System | Psma-targeted immunotherapies for cancers |
| WO2022087453A1 (en) * | 2020-10-22 | 2022-04-28 | Lyell Immunopharma, Inc. | Chimeric activation receptors |
| EP4301782A1 (en) | 2021-03-05 | 2024-01-10 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
| US20240254441A1 (en) | 2021-06-04 | 2024-08-01 | Kirin Holdings Kabushiki Kaisha | Cell composition, method for producing cell composition, and pharmaceutical composition containing cell composition |
| JP2024531915A (ja) | 2021-08-05 | 2024-09-03 | ジーオー セラピューティクス，インコーポレイテッド | 抗グリコｍｕｃ抗体およびその使用 |
| WO2023034569A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-cmet antibodies and their uses |
| JP2024534910A (ja) | 2021-09-03 | 2024-09-26 | ジーオー セラピューティクス，インコーポレイテッド | 抗グリコｌａｍｐ１抗体およびその使用 |
| MX2024003887A (es) | 2021-10-14 | 2024-07-09 | Arsenal Biosciences Inc | Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica. |
| US20260083848A1 (en) | 2021-11-03 | 2026-03-26 | Viracta Therapeutics, Inc. | Combination of car t-cell therapy with btk inhibitors and methods of use thereof |
| US20230407252A1 (en) * | 2022-04-28 | 2023-12-21 | Allogene Therapeutics, Inc. | Methods for donor cell analysis |
| US20250295773A1 (en) * | 2022-05-10 | 2025-09-25 | Miltenyi Biotec B.V. & Co. KG | Compositions comprising il-15, il-15 receptor alpha and the intracellular signaling domain of cd2 for immune cell therapy |
| TW202442689A (zh) | 2023-03-03 | 2024-11-01 | 美商亞森諾生物科學公司 | 靶向ｐｓｍａ及ｃａ９之系統 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| US8211422B2 (en) * | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| US5993434A (en) | 1993-04-01 | 1999-11-30 | Genetronics, Inc. | Method of treatment using electroporation mediated delivery of drugs and genes |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US5712149A (en) * | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| GB9526131D0 (en) * | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Recombinant chimeric receptors |
| US6277368B1 (en) * | 1996-07-25 | 2001-08-21 | The Regents Of The University Of California | Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine |
| US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
| US6241701B1 (en) | 1997-08-01 | 2001-06-05 | Genetronics, Inc. | Apparatus for electroporation mediated delivery of drugs and genes |
| US6055453A (en) | 1997-08-01 | 2000-04-25 | Genetronics, Inc. | Apparatus for addressing needle array electrodes for electroporation therapy |
| US6678556B1 (en) | 1998-07-13 | 2004-01-13 | Genetronics, Inc. | Electrical field therapy with reduced histopathological change in muscle |
| US7171264B1 (en) | 1999-05-10 | 2007-01-30 | Genetronics, Inc. | Intradermal delivery of active agents by needle-free injection and electroporation |
| EP1235842A4 (en) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| HK1052372A1 (zh) | 2000-02-24 | 2003-09-11 | Xcyte Therapies, Inc. | 细胞的同步刺激和富集 |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| WO2001066149A2 (en) | 2000-03-03 | 2001-09-13 | Valentis, Inc. | Nucleic acid formulations for gene delivery and methods of use |
| WO2001096584A2 (en) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Materials and methods for the control of nematodes |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US20030171546A1 (en) * | 2001-04-30 | 2003-09-11 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US20040014645A1 (en) | 2002-05-28 | 2004-01-22 | Advisys, Inc. | Increased delivery of a nucleic acid construct in vivo by the poly-L-glutamate ("PLG") system |
| US20050070841A1 (en) | 2002-07-04 | 2005-03-31 | Inovio As | Electroporation device and injection apparatus |
| US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
| US20050113564A1 (en) | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
| AU2005250408B2 (en) | 2004-05-27 | 2010-09-23 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| CN101370927A (zh) | 2005-12-07 | 2009-02-18 | 基因特伦尼克斯公司 | 可变容积电穿孔室以及其方法 |
| CA2735456C (en) | 2008-08-26 | 2021-11-16 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| JP5934099B2 (ja) * | 2009-10-01 | 2016-06-15 | アメリカ合衆国 | 抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用 |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| KR20140060541A (ko) * | 2011-09-16 | 2014-05-20 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암을 치료하기 위한 rna 조작된 t 세포 |
| EP2817330B1 (en) * | 2012-02-22 | 2020-07-08 | The Trustees of the University of Pennsylvania | Use of icos-based cars to enhance antitumor activity and car persistence |
| BR112014020502A2 (pt) * | 2012-02-22 | 2019-09-24 | Univ Pennsylvania | sequência de ácido nucleico isolada, receptor quimérico de antígeno isolado, célula, vetor, e, métodos para estimular uma resposta imune, para fornecer uma imunidade antitumoral, para tratamento de um mamífero, para gerar e para expandir uma população de células - t, e para modular a quantidade de citocina secretada por uma célula -t |
| KR20210149195A (ko) * | 2012-07-13 | 2021-12-08 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 형질도입된 ｔ 세포의 투여 적합성을 평가하는 방법 |
| WO2014055442A2 (en) * | 2012-10-01 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting stromal cells for the treatment of cancer |
| RU2729401C2 (ru) * | 2012-10-02 | 2020-08-06 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Композиции и способы для иммунотерапии |
| JP6831777B2 (ja) * | 2014-07-21 | 2021-02-17 | ノバルティス アーゲー | Ｃｄ３３キメラ抗原受容体を使用する癌の処置 |
| EP3712171A1 (en) * | 2014-08-19 | 2020-09-23 | Novartis AG | Treatment of cancer using a cd123 chimeric antigen receptor |
| US10093746B2 (en) * | 2014-09-04 | 2018-10-09 | The Trustees Of The University Of Pennsylvania | Glypican-3 antibody and uses thereof |
| US20180334490A1 (en) * | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
| SG11201807489PA (en) * | 2016-03-04 | 2018-09-27 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
| SG11201900885VA (en) * | 2016-08-01 | 2019-02-27 | Novartis Ag | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
| WO2019210207A2 (en) * | 2018-04-27 | 2019-10-31 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor t regulatory cells for the treatment of atherosclerosis |
| WO2020069405A1 (en) * | 2018-09-28 | 2020-04-02 | Novartis Ag | Cd22 chimeric antigen receptor (car) therapies |
| US20210347851A1 (en) * | 2018-09-28 | 2021-11-11 | Novartis Ag | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies |
| AU2019404302A1 (en) * | 2018-12-19 | 2021-08-05 | The Trustees Of The University Of Pennsylvania | Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor t cells against t cell lymphomas and leukemias |
| TW202042824A (zh) * | 2019-03-27 | 2020-12-01 | 賓夕法尼亞大學董事會 | Tn-MUC1嵌合抗原受體（CAR）T細胞療法 |
| US20200370013A1 (en) * | 2019-05-20 | 2020-11-26 | The Trustees Of The University Of Pennsylvania | Engineered Expression of Cell Surface and Secreted Sialidase by CAR T Cells for Increased Efficacy in Solid Tumors |
-
2013
- 2013-02-22 BR BR112014020502A patent/BR112014020502A2/pt not_active IP Right Cessation
- 2013-02-22 US US14/375,999 patent/US9783591B2/en active Active
- 2013-02-22 SG SG11201404284SA patent/SG11201404284SA/en unknown
- 2013-02-22 EP EP13751899.9A patent/EP2817331B1/en active Active
- 2013-02-22 WO PCT/US2013/027361 patent/WO2013126729A1/en not_active Ceased
- 2013-02-22 EA EA201491573A patent/EA201491573A1/ru unknown
- 2013-02-22 EP EP23193203.9A patent/EP4275699A3/en active Pending
- 2013-02-22 ES ES13751899T patent/ES2959443T3/es active Active
- 2013-02-22 AU AU2013222284A patent/AU2013222284A1/en not_active Abandoned
- 2013-02-22 CA CA2864489A patent/CA2864489C/en active Active
- 2013-02-22 JP JP2014558875A patent/JP2015509716A/ja not_active Withdrawn
- 2013-02-22 CN CN201380010713.XA patent/CN104136458A/zh active Pending
- 2013-02-22 KR KR20147023594A patent/KR20140127829A/ko not_active Ceased
- 2013-02-22 MX MX2014010185A patent/MX2014010185A/es unknown
- 2013-02-22 IN IN6522DEN2014 patent/IN2014DN06522A/en unknown
-
2014
- 2014-08-07 IL IL233993A patent/IL233993A0/en unknown
-
2017
- 2017-08-04 US US15/669,562 patent/US10501519B2/en active Active
-
2019
- 2019-07-02 US US16/460,221 patent/US11597754B2/en active Active
-
2021
- 2021-08-05 US US17/444,519 patent/US12234274B2/en active Active
-
2023
- 2023-02-17 US US18/170,695 patent/US20230242612A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015509717A5 (enExample) | ||
| WO2012079000A4 (en) | Use of chimeric antigen receptor-modified t cells to treat cancer | |
| Bartkowiak et al. | 4-1BB agonists: multi-potent potentiators of tumor immunity | |
| Dai et al. | Chimeric antigen receptors modified T-cells for cancer therapy | |
| Hodgins et al. | Killers 2.0: NK cell therapies at the forefront of cancer control | |
| Hillerdal et al. | Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer | |
| Baksh et al. | Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations | |
| JP6336684B2 (ja) | Ｐｄ−ｌ１によって誘導される免疫寛容の低減 | |
| JP2016520074A5 (enExample) | ||
| JP2014509841A5 (enExample) | ||
| Comoli et al. | Development of adaptive immune effector therapies in solid tumors | |
| JP2015535689A5 (enExample) | ||
| JP7662588B2 (ja) | 遺伝子操作された薬物耐性ｔ細胞およびその使用方法 | |
| JP2018029594A5 (enExample) | ||
| CN111247241A (zh) | T细胞受体缺陷型嵌合抗原受体t细胞和其使用方法 | |
| WO2016126781A4 (en) | Tnfrsf-binding agents and uses thereof | |
| JP2020530989A5 (enExample) | ||
| JP2017534633A5 (enExample) | ||
| Junghans | The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective | |
| Alsaieedi et al. | Tracing the development of CAR-T cell design: from concept to next-generation platforms | |
| RU2018118817A (ru) | Химерные рецепторы антигена, нацеленные на her2 | |
| JP2017507919A5 (enExample) | ||
| Cooper et al. | Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies | |
| CN102014937A (zh) | 基于异基因癌细胞的免疫治疗 | |
| CN111479925A (zh) | 具有y182t突变的t细胞-抗原偶联物及其方法和用途 |